In brief
What services should biopharma companies deliver to oncologists?
1. Enabling patient-specific discussions
91%
of oncologists say individual patient case discussion will influence treatment decisions in the future.
43%
of oncologists say product level discussions will influence treatment decisions in the future.
2. Building real-world data capabilities
65%
of oncologists want pharma representatives to be able to discuss RWD with them.
3. Expanding precision oncology support
4. Getting the basics right
Ground-breaking treatments are great, but if access is constrained by complexity, the treatments won’t create the experiences and outcomes oncologists and patients require.
How should the services be delivered?
Who should deliver the support?
Act now to be future ready
Visit our Subscription and Preference Center